155 results about "Fibrinogen" patented technology

The invention discloses a preparation method and application of autologous fibrin glue, and belongs to the field of biomedical materials. The preparation method comprises the following five steps: collecting autologous venous blood, adding a sodium citrate anticoagulant with the volume ratio of 1: (8-12), and storing at 4-6 DEG C for not more than 2 hours; performing step-by-step centrifugation at the speed of 1500 to 2000 r / min and the speed of 3500 to 4000 r / min to obtain a fibrinogen concentrate; the thrombin-calcium chloride activation solution A and the tranexamic acid activation solution B are mixed according to the ratio of 1: (2-3) to form a composite activation system; mixing the two components according to a mass ratio of 1: (0.8-1.2), and reacting at 25-37 DEG C for 3-5 minutes to form colloid; and pre-freezing at-40 to-60 DEG C, performing vacuum freeze-drying, and storing at 4-8 DEG C. During application, the colloid can be coated on an operation wound surface after being redissolved, or mixed with a growth factor to prepare a dressing for covering a chronic wound surface. The colloid is high in purity, stable in coagulation time, long in storage period, suitable for scenes such as surgical hemostasis and the like, and high in clinical value.

The invention provides autologous platelet-containing plasma gel and a preparation method and application thereof, and relates to the technical field of biological medicine and tissue engineering.The preparation method comprises the following steps that peripheral venous blood of a patient is extracted and added into a centrifugal tube mixed with a sodium citrate anticoagulant; putting the centrifugal tube into a centrifugal machine for centrifuging, and taking upper-layer plasma; wherein the upper-layer plasma refers to plasma between the upper-layer liquid level and the lower-layer red blood cell layer by 1mm; the centrifugal speed ranges from 1300 r / min to 1700 r / min; the centrifugation time is 3-5 min; under a sterile condition, preparing a calcium gluconate / thrombin mixed solution; and dropping the calcium gluconate / thrombin mixed solution into the upper plasma, mixing, and solidifying to obtain the autologous platelet-containing plasma gel. After one-time centrifugation, upper-layer full-layer plasma is extracted, the volume of the prepared gel is far larger than that of a traditional method, the utilization rate of whole blood platelets and fibrinogen is close to 100%, and regeneration and repair of large-area tissue wounds can be met.

The invention discloses biological glue and a preparation method thereof.The preparation method comprises the steps that gel and activation liquid are prepared, and the gel is prepared by evenly mixing I-type collagen freeze-dried powder, chitosan and a fibrinogen solution; and mixing the freeze-dried thrombin with a calcium chloride solution to prepare an activation solution. The meninx suturing device has the advantages that sliding in the meninx suturing process is effectively reduced, an operation is easier to carry out, the risk that the meninx or a repairing material slides after the operation can be reduced, and a wound is evenly healed; most of the components are type I collagen which is beneficial to meninx injury repair, and the components contain chitosan which has antibacterial and hemostatic effects.

Disclosed is a method for filtering a fibrinogen composition, including the following steps: a) purifying the fibrinogen composition by chromatographic purification using an elution buffer comprising arginine; b) optionally, at least one step of filtering the fibrinogen composition obtained by chromatographic elution in step a), on a filter having a pore size of between 0.08 μm and 0.22 μm, c) filtering the fibrinogen composition obtained by chromatographic elution in step a), or optionally obtained in step b), on a symmetrical filter having a pore size of between 15 nm and 25 nm, and preferably between 18 nm and 22 nm, and d) recovering the resulting fibrinogen solution, the filtering method being carried out without adding arginine after step a), at a high capacity and without a prior freezing and / or thawing step.

A system for determining a functional fibrinogen concentration from a patient's coagulating blood or blood plasma sample is configured to obtain a signal representing physical or biochemical properties of the developing fibrin network during coagulation of the patient's blood or blood plasma sample over time, determine the fibrinogen concentration based on one or more values of one or more features of the signal with the help of a learned function which maps values of the feature(s) to functional fibrinogen concentrations, and output the fibrinogen concentration, e.g. on a display. The feature(s) include(s) multiple of features related to 1) a maximum value of the gradient of the signal, 2) the maximum of the second derivative of the signal, 3) a difference between the maximum and the minimum of the signal, and 4) the minimum of the second derivative of the signal, or at least feature 1) or 2).

The invention discloses a preparation method of a fibrous protein / bacterial cellulose efficient hemostatic patch. The preparation method comprises the following steps: (1) in-situ preparation of large-aperture bacterial cellulose; (2) infiltration of fibrinogen in the large-aperture bacterial cellulose; and (3) enzyme digestion and freeze-drying treatment of fibrinogen. The problems that fibrinogen is fast in degradation and poor in stability and mechanical property are solved, the prepared fibrous protein / bacterial cellulose efficient hemostatic patch can prevent secondary bleeding and avoid thrombus to a certain extent, the preparation process is simple and easy to implement, and large-scale preparation and storage can be achieved.

The present invention is applicable to the technical field of bone defect repair, and provides a preparation method and application of a collateral-modified Gelma hydrogel. The present invention performs collateral modification on the Gelma hydrogel by Fibrinogen, successfully improving the mechanical properties and cell adhesion of the hydrogel scaffold. At the same time, the loading of NELL‑1 protein significantly improves the scaffold's ability to repair bone defects. The Fibrinogen‑Gelma / NELL‑1 hydrogel scaffold constructed by the present invention has shown ideal mechanical properties in relevant characterizations, and has been shown to play a key role in the repair of bone tissue defects in in vitro and in vivo experiments, and has greatly promoted the expression of osteogenesis-related genes. Therefore, the present invention is expected to be applied to clinical treatments related to bone defect repair, such as maxillary sinus bone augmentation and guided bone regeneration (GBR), in the future.

The utility model discloses a hemostasis assist device for vascular surgery, which relates to the technical field of medical instruments, and comprises a fixing mechanism, a vascular surgery hemostasis mechanism is arranged in the fixing mechanism, the vascular surgery hemostasis mechanism comprises a knob, and the bottom of the knob is fixedly connected with a threaded column. According to the hemostasis mechanism for the vascular surgery department, during hemostasis, the periphery of a wound can be heated through the heating block across the replacement pad, the temperature of the periphery of the wound reaches 37-42 DEG C, activation of platelets can be accelerated to a certain extent at the temperature, energy metabolism of the platelets is accelerated within the temperature range, and the blood circulation is accelerated. The increase of the concentration of calcium ions in the blood platelets is an important signal of platelet activation, and the increased concentration of the calcium ions can promote the activation of glycoprotein receptors on platelet membranes, so that the binding capacity of the blood platelets and fibrinogen is enhanced, the aggregation of the blood platelets is accelerated, and the hemostasis speed is accelerated.

The invention relates to the technical field of electrochemical sensing, in particular to a multi-channel electrochemical aptamer sensor and a preparation method and application thereof.The multi-channel electrochemical aptamer sensor adopts a commercial silk-screen printing electrode and is combined with a polymer substrate material for amplifying electrochemical signals, and the electrochemical aptamer sensor is prepared. According to the present invention, the corresponding aptamer is fixed by using the gold nanoparticle through the chemical bond so as to specifically detect the three hemorrhage conversion biomarkers after acute cerebral infarction, such as human matrix metalloproteinase (MMP-9), fibrinogen (FN) and plasminogen activation inhibitor (PAI-1); wherein the FN and the PAI-1 are detected through an electrochemical aptamer sensor method for the first time, and simultaneous detection of the three biomarkers is realized through integration with commercial multi-channel micro electrochemical equipment.

The present application relates to a method for preparing and expanding a TSCM cell in vitro. Specifically, the method comprises: 1) obtaining an isolated CD8+ T cell; 2) activating the CD8+ T cell; 3) mixing the activated CD8+ T cell, a fibrinogen solution and a thrombin solution, and culturing same under conditions suitable for cell growth, so as to obtain a TSCM cell culture; and 4) bringing the culture into contact with a dispase so as to obtain a TSCM cell. The present application also relates to a kit for preparing and expanding a TSCM cell in vitro, the use of fibrinogen and thrombin in the preparation of a kit for preparing and expanding a TSCM cell in vitro, and a TSCM cell obtained by means of the method or kit of the present application.

To provide compositions containing RPE cells or RPE monolayers, as well as methods and materials for making RPE cells or RPE monolayers from, for example, stem cells (e.g., iPSCs).SOLUTION: Disclosed is a method for making a retinal pigment epithelium monolayer, the method comprising, or consisting essentially of, culturing stem cells in a container having a surface coated with fibrinogen, wherein the surface is coated with greater than 3 μg / mL of fibrinogen, wherein the cells are in contact with the fibrinogen, and wherein the cells form the retinal pigment epithelium monolayer.SELECTED DRAWING: None

The invention belongs to the technical field of biomedical material engineering, and discloses a hydrogel scaffold used for 3D tumor sphere culture and drug screening, the scaffold is formed by four-arm polyethylene glycol maleimide, fibrinogen and thrombin through Michael addition crosslinking and biopolymerization synergistically, the elastic modulus of 10-1000 Pa can be adjusted by regulating and controlling the proportion of all the components, and the hydrogel scaffold can be used for 3D tumor sphere culture and drug screening. Gel forming is completed within 5 min at the room temperature. The scaffold has the biological activity of fibrous protein and the structural stability of polyethylene glycol, can efficiently support HCT116 cells to form high-activity tumor balls, accurately simulate the in-vivo tumor microenvironment and remarkably improve the accuracy and repeatability of drug screening, is easy and convenient to operate, is compatible with a standard pore plate high-throughput platform and is suitable for drug sensitivity detection of personalized treatment of tumors.

The present invention provides for a novel method for the detection of the presence of myasthenia gravis in a subject, by means of detecting the presence of fibrinogen in serum generated from the blood of the patient. Further novel means for stabilizing the fibrinogen, for the purposes of interrogation of the sample, are provided.

Described herein are multi-specific antigen-binding proteins that bind human fibrin γC or fibrinogen γC domain and vascular endothelial growth factor, and methods of use thereof. In some embodiments, described herein are pharmaceutical compositions comprising the multi-specific antigen-binding proteins that bind fibrin γC or fibrinogen γC domain and vascular endothelial growth factor. In some embodiments, the multi-specific antigen-binding proteins and methods described herein are used for treatment of disorders or conditions of the eye.

The invention discloses a special constant-temperature thawing and dissolving device for medical fibrinogen, and relates to the technical field of medical auxiliary instruments, the special constant-temperature thawing and dissolving device for medical fibrinogen comprises a heat preservation box body, and a circulating hot water supply device, a constant-temperature preheating tank, an infusion doser and a dissolving tank which are integrated in the heat preservation box body, the circulating hot water supply device is arranged on one side of an inner cavity of the heat preservation box body; a porous placing frame is placed in the constant-temperature preheating tank, a disposable pipetting mechanism is arranged on the infusion doser, a magnetic shaking table is installed in the center of an inner cavity of the dissolving tank, the preheating function and the dissolving function are integrated into one device, hot water is conveyed to the constant-temperature preheating tank through the circulating hot water supply device for preliminary preheating, and then medicine bottles are transferred to the dissolving tank for dissolving; the process is orderly linked, the tedious step-by-step operation is avoided, the pollution risk is reduced, the operation is simplified, medical fibrinogen thawing and dissolving can be more efficiently and stably completed, and the working efficiency and quality are improved.

A method of detecting inflammation in a subject is provided. The method comprises determining a quantity of amyloid present in fibrin(ogen) protein in a blood sample obtained from the subject, and assigning a level of inflammation in the subject based on the quantity of fibrin(ogen) amyloid determined. A method of determining an effect of a therapeutic treatment on a subject by comparing a pre-treatment level of inflammation with a post-treatment level is further provided.

The invention relates to a freeze drying method of instant fibrinogen, and belongs to the technical field of blood product preparation. The method comprises the steps of plasma pre-fusion, centrifugal separation, FI extraction, FI precipitation, dissolution and filtration, polyethylene glycol purification and separation, S / D inactivation, ethanol purification and separation, glycine purification and separation, ultrafiltration dialysis, preparation, degerming and subpackaging, freeze-drying and capping and the like. Wherein the freeze-drying process comprises four stages of pre-freezing, primary sublimation, desorption drying and plug pressing, and finally dry heat inactivation treatment is carried out. According to the method, efficient extraction and purification of fibrinogen are achieved by accurately controlling the temperature, the time, the pH value and the component proportion of various solutions in each step, and the obtained product has good instant dissolving performance and can be used in the medical fields of clinical hemostasis, tissue repair and the like.

The invention discloses a preparation method and application of hemostatic peptide with a self-assembly function, and relates to the technical field of biomedical materials. The hemostatic peptide disclosed by the invention has the beneficial effects that the hemostatic peptide has the capability of forming long and uniform nanobelts through self-assembly. The hemostatic peptide is quickly gelated through self-assembly, adsorbs red blood cells and platelets, seals wounds and promotes fibrinogen to be converted into fibrin, so that efficient and quick hemostasis is realized. The haemostatic peptide has high stability, low toxicity and good biocompatibility, can be widely applied to haemostatic scenes of wounds, operations, burns and the like, and provides a novel and efficient haemostatic means for medical first aid and surgical operations.

The application belongs to the technical field of biological medicine, and discloses application of a simulation polypeptide containing a fibrinogen RGD module in preparation of a medicine for preventing and / or treating Parkinson's disease. The sequence of the simulation polypeptide containing the fibrinogen RGD module is Gly-Arg-Gly-Asp-Ser-Pro-Lys-Asn-Pro-Ser-Cys. The applicant of the application finds that FG abnormally accumulates in the substantia nigra compacta of a PD mouse, and the FG excessively accumulated in the brain may promote abnormal aggregation of alpha-syn of dopaminergic neurons through mediation of an alpha v beta 3 integrin receptor. The simulation polypeptide provided by the application can effectively inhibit abnormal aggregation of alpha-syn of dopaminergic neurons caused by the abnormally accumulated FG in the brain and death of the dopaminergic neurons, improve the motor ability of the PD mouse modeled by MPTP, and provide a new target and thought for PD treatment.

Provided is a protein having a hexamer structure in which two molecules of a heterotrimeric protein associate at the N-terminus side, wherein the heterotrimeric protein is composed of (1) a fibrinogen Aα chain deficient in fibrinopeptide A, (2) a fibrinogen Bβ chain deficient in fibrinopeptide B and losing the ability to bind to B knob, and (3) a fibrinogen γ chain losing the ability to bind to A knob. The protein of the present invention can be used as a carrier for imparting physiological activity to fibrin gel in a thrombin-independent manner.

A protein nanospheres and method to treat dysfunction from chemotherapy and immunosuppressive therapy, and a manufacture of fibrinogen-coated albumin spheres (FAS) and High-Fibrinogen Spheres (HFS) which have higher concentrations of fibrinogen molecules per sphere than FAS, and their use for medical treatments. Both kinds of nanoparticles are effective in the mitigation of the toxic effects of certain chemotherapeutic and radiological agents that are typically used in the treatment of cancer, or the treatment of autoimmune diseases, or for patients with both diseases. FAS and HFS can exert their beneficial effects via a variety of mechanisms which match the need of the body for specific cell types, including any of the subgroups of T cells and antibody producing cells, the relative concentration of each kind is vital to the balance between tumor surveillance and autoimmune disease suppression.

A method and kit for stopping cerebrospinal fluid (CSF) leakage, comprising penetrating and passing an applicator through dural tissue to access the inner dural space, injecting a fibrinogen-containing solution from the applicator into the dural space, applying a sealing member containing a fibrinogen polymerizing agent to the outer surface of the dural tissue, and forming polymerized fibrinogen or a polymerized fibrin clot by contacting the injected fibrinogen-containing solution with the fibrinogen polymerizing agent.

The present invention belongs to the fields of polypeptide synthesis and biomedicine technology, and specifically relates to a polypeptide PM7 and its application in preventing and treating thrombosis. The present invention obtains an original polypeptide from the transcriptome of the salivary gland of the leech Philippine cattle leech, and truncates the original polypeptide to bind to the fibrinogen binding site of thrombin, thereby interfering with the activity of thrombin. Furthermore, {d-Phe}-PRP is added to the N-terminus of the truncated polypeptide, and {d-Phe}-PRP and the truncated polypeptide are connected with a connecting polypeptide to obtain the polypeptide PM7. The polypeptide PM7 of the present invention has the activity of inhibiting thrombin, has a shorter half-life in the body, and is highly safe, thereby achieving the effect of preventing and treating thrombosis.

The invention discloses plasmin based on hermetia illucens and application thereof, and belongs to the technical field of biology. The plasmin based on the hermetia illucens is obtained by grinding and centrifuging larvae of the hermetia illucens in a PBS (Phosphate Buffer Solution) and extracting supernate. The invention further provides application of the plasmin based on the hermetia illucens in preparation of thrombolytic drugs. The plasmin is extracted from the hermetia illucens, and the hermetia illucens is short in breeding cycle, high in reproductive capacity, capable of being massively extracted in a short time and low in cost; the extracted plasmin has a remarkable thrombolysis effect and has a very good utilization value; the plasmin can be used for directly dissolving thrombus and degrading fibrinogen.

The present invention discloses a method for simultaneously separating canine fibrinogen and canine prothrombin complex from canine plasma. First, rough separation and fine separation are carried out by gel column chromatography and anion column chromatography. Then, further purification is carried out by DEAE Sephadex A-50 gel adsorption. Through the combination of multiple steps of processes and their parameters, high-purity and high-yield canine fibrinogen, prothrombin and other components can be extracted from canine plasma simultaneously. The purity of both canine fibrinogen and canine prothrombin complex can reach over 95%, and the extraction rates of canine fibrinogen and canine prothrombin complex reach over 90% and over 85% respectively, greatly improving the comprehensive utilization rate of canine plasma. At the same time, by adjusting the formula and ratio of the stabilizer, the freeze-dried products of canine fibrinogen and canine prothrombin complex have good solubility, clear solutions, and short reconstitution times, which are 10-15 minutes and 5-10 minutes respectively. In summary, the method of the present invention has stable processes, high raw material utilization rate, and good product quality.

The present technique pertains to a method of preparation of a succinylated collagen-fibrinogen hydrogel and a succinylated collagen-fibrinogen hydrogel prepared thereby. The method of preparation of a succinylated collagen-fibrinogen hydrogel according to the present technique can produce a collagen-based bio-substance in a simple process, wherein collagen can be prevented from being entangled and an improvement can be brought about in hydrophilicity, cell growth rate, cell compatibility, and cell diffusion capability, whereby the collagen-based bio-substance exhibits excellent biocompatibility in vivo.

Fibrinogen-coated Albumin Nanospheres (FAS) has shown that it can mobilize bone marrow cells into the blood which then go to injured soft and hard tissues to achieve accelerated repair. It is hypothesize that (a) brain injuries caused by low-dose irradiation under simulated microgravity can be mitigated by the administration of FAS; and (b) the mechanism is from acceleration of neo-vascularization, proven by lineage study of GFP-labeled bone marrow cells implanted into compatible non-GFP animals before injury, which regenerate into functional GFP-brain cells after FAS treatment.

The present invention provides a cell composition, a method for producing a hydrogel cell composition, and the like. In the cell composition, cells are suspended in a solution containing dimethyl sulfoxide at 5.0 v / v% or more and 10.0 v / v% or less and albumin at 2.0 w / v% or more and 5.0 w / v% or less. This method for producing a hydrogel cell composition comprises a step for preparing a hydrogel cell composition by mixing a cell composition containing dimethyl sulfoxide, albumin, and cells, fibrinogen, and thrombin. The cell composition contains 5.0 v / v% or more and 10.0 v / v% or less of dimethyl sulfoxide, 2.0 w / v% or more and 5.0 w / v% or less of albumin, and one or more cells selected from the group consisting of chondrocytes and adipose-derived mesenchymal stem cells.

The invention relates to an application of Fgl2 gene knockout in antagonism of new coronavirus. In the technical scheme provided by the invention, a new crown infected mouse model is established through two SARS-CoV-2 mouse adaptive strains, namely, an MA17 strain and an MASCp36 strain, and it is verified that virus infection can promote Fgl2 expression up-regulation and fibrinogen deposition in mouse lung tissues; in addition, an SARS-CoV-2 mouse adaptive strain MA17 is utilized to infect an Fgl2 gene knockout mouse to prove that the Fgl2 gene knockout can antagonize lung inflammation infiltration, tissue damage, thromboembolism, fibrinogen deposition and fibrosis formation caused by virus infection, so that the occurrence of severe case and death of the mouse is reduced.

The invention belongs to the technical field of enzyme engineering and molecular biology, and particularly relates to serine peptidase, a nucleic acid molecule and application of the serine peptidase. According to the invention, three kinds of serine peptidase SpBcA, SpBcB and SpBcC are identified in B. cardium for the first time, and the structures and functions of the three kinds of serine peptidase SpBcA, SpBcB and SpBcC are analyzed. SpBcA and SpBcB have good serine peptidase activity, can tolerate high temperature (the optimum enzyme reaction temperature is 60 DEG C), and have good activity under an alkaline condition. It is further found that SpBcA is generated in the form of zymogen and is subjected to self-splitting. An inhibitory propeptide is arranged at the N end and can be used as a molecular chaperone to inhibit the activity of the molecular chaperone, and a novel activity mechanism is shown. In addition, the SpBcA serine peptidase can degrade various substrates such as casein, fibrinogen, antibacterial peptide LL-37, gelatin and the like. Therefore, as a novel serine peptidase, the serine peptidase has potential industrial and medical application values.